All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Which tests are needed for risk stratification in ALL

Jul 29, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL

During the last steering committee (SC) meeting, held on May 19, 2022, the SC members discussed the tests needed for risk stratification in ALL. The session was chaired by Jan Cools and included Oliver Ottmann, Sabina Chiaretti, Wendy Stock, Hervé Dombret, Mark Litzow, and André Baruchel.

Key topics of discussion included: “Why should genetics and MRD assessments be combined” and “Is there an optimal time point for MRD testing.”

Which tests are needed for risk stratification in ALL

More about...